NEO
NeoGenomics, Inc. · Healthcare
Insiders sold $968K of NeoGenomics, Inc. in the last 12 months and bought none
NEO over the last year
NEO after insider buys
3 months after each buy, from the first price a copier could get.
7 buys since 2016 with 3 months of prices.
Congress
Members reported 2 trades in NEO since 2025.
Every filing
103 insider filings since 2016, newest first
Greg D Aunan · Chief Accounting Officer
Lynn A. Tetrault · Director
Lynn A. Tetrault · Director
Warren Stone · President and COO
Alicia C Olivo · EVP, GC, Business Development
Jeffrey Scott Sherman · CFO
Anthony P. Zook · CEO
Michael Aaron Kelly · Director
Warren Stone · President and COO
Lynn A. Tetrault · Director
Stephen M Kanovsky · Director
Anthony P. Zook · CEO
David Brian Perez · Director
Neil Gunn · Director
Jeffrey Scott Sherman · CFO
Alicia C Olivo · General Counsel
Lynn A. Tetrault · Director
Alicia C Olivo · General Counsel
Alicia C Olivo · General Counsel
William Bonello · CFO
Kathryn B Mckenzie · CFO
William Bonello · Pres, Informatics
Douglas Matthew Brown · Chief Strategy Officer
Bruce K Crowther · Director
George Cardoza · Pres, Pharma Services
Robert J. Shovlin · Pres, Clinical Services
Lawrence Martin Weiss · Chief Medical Officer
Steven C Jones · Director
Jennifer Balliet · VP and Chief Culture Officer
Steven C Jones · Director
Kevin C Johnson · Director
William Bonello · Pres, Informatics
George Cardoza · Pres, Pharma Services
Raymond R Hipp · Director
Oort Douglas M Van · Chair and CEO
Denise E Pedulla · General Counsel
Steven C Jones · Director
Bruce K Crowther · Director
Steven C Jones · Director
George Cardoza · Pres, Pharma Services
William Bonello · Pres, Informatics
Jennifer Balliet · VP and Chief Culture Officer
Robert J. Shovlin · Pres, Clinical Services
Robert J. Shovlin · Pres, Clinical Services
Steven C Jones · Director
Kathryn B Mckenzie · Chief Accounting Officer
Steven C Jones · Director
Oort Douglas M Van · Chair and CEO
Jennifer Balliet · VP and Chief Culture Officer
George Cardoza · Pres, Pharma Services
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.